Viewing Study NCT04215159

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 2:54 PM
Ignite Modification Date: 2026-02-03 @ 10:41 AM
Study NCT ID: NCT04215159
Status: UNKNOWN
Last Update Posted: 2020-01-02
First Post: 2019-09-24
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Trastuzumab Biosimilar (Samfenet®) Plus Treatment of Physician's Choice (TPC) in Patients With HER2-positive Solid Tumor
Sponsor: Jin-Hee Ahn
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None HER-2 Protein Overexpression View
None HER-2 Gene Amplification View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HER-2 Protein Overexpression View
None HER-2 Gene Amplification View
None HER2 targeted-treatment View
None Trastuzumab biosimilar View
None samfenet View